YMAB [NASD]
Y-mAbs Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.67 Insider Own0.50% Shs Outstand43.71M Perf Week11.01%
Market Cap373.27M Forward P/E- EPS next Y-1.42 Insider Trans-83.47% Shs Float38.32M Perf Month-20.45%
Income-116.80M PEG- EPS next Q-0.69 Inst Own63.20% Short Float7.53% Perf Quarter24.59%
Sales40.00M P/S9.33 EPS this Y57.00% Inst Trans-6.42% Short Ratio5.90 Perf Half Y-48.08%
Book/sh3.60 P/B2.74 EPS next Y11.50% ROA-51.70% Target Price28.17 Perf Year-72.59%
Cash/sh4.15 P/C2.38 EPS next 5Y- ROE-59.70% 52W Range6.50 - 39.82 Perf YTD-39.05%
Dividend- P/FCF- EPS past 5Y-19.60% ROI-64.10% 52W High-75.19% Beta1.40
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin89.90% 52W Low52.00% ATR1.07
Employees148 Current Ratio6.10 Sales Q/Q94.40% Oper. Margin- RSI (14)48.87 Volatility10.05% 12.52%
OptionableYes Debt/Eq0.00 EPS Q/Q-185.30% Profit Margin- Rel Volume0.80 Prev Close9.52
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume489.15K Price9.88
Recom1.90 SMA203.16% SMA50-10.01% SMA200-45.45% Volume394,417 Change3.78%
Feb-03-22Resumed Guggenheim Buy $22
Nov-19-21Resumed Morgan Stanley Equal-Weight $25
Nov-16-21Downgrade JP Morgan Overweight → Neutral $57 → $30
May-07-21Upgrade BofA Securities Neutral → Buy
Apr-23-21Resumed Cowen Outperform
Mar-22-21Resumed JP Morgan Overweight $57 → $52
Jan-15-21Downgrade BofA Securities Buy → Neutral $56
Nov-09-20Reiterated H.C. Wainwright Buy $52 → $65
May-05-20Initiated Barclays Overweight $44
May-01-20Initiated Janney Buy
Apr-29-20Initiated Morgan Stanley Equal-Weight
Dec-24-19Initiated JP Morgan Overweight $39
Nov-20-19Initiated Guggenheim Buy
Sep-04-19Initiated Wedbush Outperform
Apr-01-19Initiated H.C. Wainwright Buy $36
Oct-16-18Initiated BTIG Research Buy $35
Oct-16-18Initiated BofA/Merrill Buy $26
May-09-22 05:25PM  
04:01PM  
May-03-22 04:01PM  
Apr-28-22 03:02PM  
Apr-27-22 04:01PM  
Apr-21-22 08:16AM  
Apr-08-22 09:00AM  
Apr-01-22 09:00AM  
Mar-21-22 10:14AM  
Mar-07-22 04:51AM  
Feb-24-22 05:40PM  
04:01PM  
Feb-17-22 03:02PM  
09:00AM  
Feb-14-22 10:29AM  
Feb-11-22 09:00AM  
Feb-01-22 08:11AM  
Jan-21-22 10:31AM  
Jan-05-22 09:00AM  
Dec-15-21 09:53AM  
09:00AM  
Dec-06-21 04:05PM  
Nov-10-21 08:32PM  
Nov-04-21 06:45PM  
04:05PM  
09:00AM  
Oct-28-21 04:01PM  
Oct-08-21 12:01PM  
Oct-07-21 09:00AM  
Sep-16-21 09:00AM  
Sep-13-21 09:00AM  
Sep-10-21 09:00AM  
Sep-08-21 07:54PM  
Aug-09-21 01:44AM  
Aug-05-21 06:05PM  
04:01PM  
Jul-29-21 04:05PM  
Jul-06-21 08:37AM  
Jun-25-21 09:00AM  
Jun-23-21 09:00AM  
Jun-22-21 06:54AM  
Jun-04-21 09:05AM  
09:00AM  
May-20-21 12:30PM  
May-19-21 04:01PM  
May-13-21 09:00AM  
May-07-21 07:15AM  
May-06-21 05:50PM  
04:01PM  
Apr-29-21 04:01PM  
09:00AM  
Apr-27-21 04:01PM  
Apr-23-21 07:27AM  
Apr-20-21 12:18PM  
09:00AM  
Apr-12-21 09:00AM  
Apr-09-21 10:24AM  
Feb-28-21 11:46PM  
Feb-26-21 06:45AM  
Feb-25-21 04:01PM  
04:50AM  
Feb-22-21 04:01PM  
Feb-19-21 09:00AM  
Feb-18-21 05:20AM  
Feb-17-21 07:14PM  
Feb-16-21 04:01PM  
Jan-06-21 09:00AM  
Dec-28-20 09:00AM  
Dec-18-20 09:05AM  
09:00AM  
Dec-16-20 09:00AM  
Dec-10-20 04:50PM  
Dec-09-20 09:00AM  
Dec-07-20 09:00AM  
Dec-04-20 12:06PM  
09:00AM  
Nov-25-20 05:02PM  
Nov-19-20 09:00AM  
Nov-06-20 04:01PM  
Nov-05-20 04:01PM  
Oct-29-20 09:00AM  
Oct-28-20 03:02PM  
Oct-26-20 09:10AM  
Oct-16-20 09:00AM  
Oct-14-20 09:00AM  
Oct-09-20 09:00PM  
Oct-08-20 05:34PM  
01:05PM  
Oct-07-20 09:00AM  
Oct-06-20 08:24AM  
Oct-05-20 04:01PM  
Aug-06-20 04:01PM  
09:00AM  
Aug-04-20 09:00AM  
Jul-27-20 04:01PM  
Jul-14-20 09:00AM  
Jul-05-20 03:05PM  
Jun-30-20 04:01PM  
Jun-02-20 09:00AM  
May-22-20 11:58AM  
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kruse BoEVP, CFO, Secretary & Treas.Feb 22Sale7.854,00031,400181,077Feb 23 05:15 PM
Gad ThomasSee remarksFeb 09Sale6.9664,276447,117565,032Feb 09 06:59 PM
Gad ThomasSee remarksFeb 08Sale7.01125,863882,891629,308Feb 09 06:59 PM
Gad ThomasSee remarksFeb 07Sale7.5991,031691,180755,171Feb 09 06:59 PM
Kruse BoEVP, CFO, Secretary & TreasFeb 04Sale7.974,00031,880185,077Feb 07 05:16 PM
Gad ThomasSee remarksFeb 04Sale7.70101,104778,531846,202Feb 07 05:15 PM
Gad ThomasSee remarksFeb 03Sale7.9035,060277,027947,306Feb 07 05:15 PM
Gad ThomasSee remarksFeb 01Option Exercise2.008,00016,00058,000Feb 03 05:00 PM
Gad ThomasSee remarksFeb 01Sale10.158,00081,16150,000Feb 03 05:00 PM
Gad ThomasSee remarksJan 24Sale10.6388,055936,412982,366Jan 26 05:09 PM
Kruse BoEVP, CFO, Secretary & Treas.Jan 24Sale9.844,00039,360189,077Jan 25 05:01 PM
Gad ThomasSee remarksJan 21Sale10.7570,318755,8151,070,421Jan 24 05:39 PM
Gad ThomasSee remarksJan 20Sale11.33112,7671,277,2891,140,739Jan 24 05:39 PM
Gad ThomasSee remarksJan 19Sale10.8969,414756,0921,253,506Jan 20 05:13 PM
Gad ThomasSee remarksJan 18Option Exercise2.008,00016,00058,000Jan 20 05:13 PM
Gad ThomasSee remarksJan 18Sale11.464004,5841,322,920Jan 20 05:13 PM
Gad ThomasSee remarksJan 18Sale11.548,00092,31450,000Jan 20 05:13 PM
Kruse BoEVP, CFO, Secretary & Treas.Jan 04Sale17.124,00068,480193,077Jan 05 05:15 PM
Kruse BoEVP, CFO, Secretary & Treas.Dec 22Sale16.364,00065,440197,077Dec 23 04:55 PM
Gad ThomasSee remarksDec 07Sale17.5810,000175,8321,383,320Dec 08 05:18 PM
Kruse BoEVP, CFO, Secretary & Treas.Dec 06Sale16.354,00065,400201,077Dec 07 05:16 PM
Gad ThomasSee remarksDec 06Sale16.4844,000725,2421,393,320Dec 08 05:18 PM
Gad ThomasSee remarksNov 30Sale17.0625,170429,4581,437,320Dec 01 05:15 PM
Gad ThomasSee remarksNov 29Sale17.1622,437385,0261,462,490Dec 01 05:15 PM
Gad ThomasSee remarksNov 23Option Exercise2.0050,000100,000100,000Nov 26 05:33 PM
Gad ThomasSee remarksNov 23Sale17.0650,000852,85050,000Nov 26 05:33 PM
Kruse BoEVP, CFO, Secretary & Treas.Nov 22Sale18.094,00072,360205,077Nov 23 05:06 PM
Gad ThomasSee remarksNov 16Sale19.334,00077,3021,484,927Nov 18 05:18 PM
Kruse BoEVP, CFO, Secretary & Treas.Nov 04Sale27.544,000110,160209,077Nov 05 05:16 PM
Gad ThomasSee remarksOct 29Sale24.824,00099,2611,488,927Nov 01 05:15 PM
Kruse BoEVP, CFO, Secretary & Treas.Oct 22Sale25.944,000103,760213,077Oct 26 06:04 PM
Gad ThomasSee remarksOct 15Sale27.204,000108,7991,492,927Oct 19 05:17 PM
Kruse BoEVP, CFO, Secretary & Treas.Oct 04Sale28.784,000115,120217,077Oct 05 05:16 PM
Gad ThomasSee remarksSep 30Sale28.264,000113,0541,496,927Oct 04 05:17 PM
Kruse BoEVP, CFO, Secretary & Treas.Sep 22Sale30.824,000123,280221,077Sep 23 05:15 PM
Gad ThomasSee remarksSep 15Sale33.644,000134,5791,500,927Sep 17 05:20 PM
Gad ThomasSee remarksSep 07Option Exercise2.0050,000100,00050,000Sep 07 05:30 PM
Kruse BoEVP, CFO, Secretary & Treas.Sep 07Sale32.034,000128,120225,077Sep 08 05:31 PM
Gad ThomasSee remarksSep 02Sale33.1850,0001,658,9151,504,927Sep 07 05:30 PM
Kruse BoEVP, CFO, Secretary & Treas.Aug 23Sale28.604,000114,400229,077Aug 24 05:02 PM
Gad ThomasSee remarksAug 17Sale28.961,77951,5271,554,927Aug 17 06:32 PM
Gad ThomasSee remarksAug 16Sale29.3026,111765,0711,556,706Aug 17 06:32 PM
Gad ThomasSee remarksAug 13Sale31.011,11034,4261,582,817Aug 17 06:32 PM
Rajah VigneshSVP & CMOAug 12Buy29.951,37441,1473,071Aug 13 05:41 PM
Kruse BoEVP, CFO, Secretary & Treas.Aug 04Sale33.724,000134,880233,077Aug 05 05:20 PM
Gad ThomasSee remarksAug 03Sale33.734,000134,9271,583,927Aug 05 05:18 PM
Kruse BoEVP, CFO, Secretary & Treas.Jul 22Sale34.504,000138,000237,077Jul 26 06:19 AM
Gad ThomasSee remarksJul 20Sale32.474,000129,8751,587,927Jul 21 06:56 PM
Gad ThomasSee remarksJul 07Sale31.874,000127,4651,591,927Jul 08 05:16 PM
Kruse BoEVP, CFO, Secretary & Treas.Jul 06Sale34.154,000136,600241,077Jul 07 06:00 PM
Kruse BoEVP, CFO, Secretary & Treas.Jun 22Sale36.174,000144,680245,077Jun 23 04:30 PM
Gad ThomasSee remarksJun 14Sale35.804,000143,2171,599,927Jun 15 05:06 PM
WG Biotech ApSDirectorJun 10Sale36.1511,229405,9714,178,456Jun 11 05:01 PM
Wedell-Wedellsborg JohanDirectorJun 10Sale36.1511,229405,9714,178,465Jun 11 05:00 PM
Wedell-Wedellsborg JohanDirectorJun 09Sale36.19116,7004,223,1164,189,694Jun 10 06:35 PM
WG Biotech ApSDirectorJun 09Sale36.19116,7004,223,1164,189,694Jun 10 07:00 PM
WG Biotech ApSDirectorJun 08Sale35.2833,3001,174,6944,306,394Jun 10 07:00 PM
Wedell-Wedellsborg JohanDirectorJun 08Sale35.2833,3001,174,6944,306,394Jun 10 06:35 PM
WG Biotech ApS10% OwnerJun 07Sale34.1572,4002,472,5834,339,694Jun 09 06:51 PM
Wedell-Wedellsborg JohanDirectorJun 07Sale34.1572,4002,472,5834,339,694Jun 09 06:49 PM
Kruse BoEVP, CFO, Secretary & Treas.Jun 04Sale33.484,000133,920249,077Jun 07 04:30 PM
WG Biotech ApS10% OwnerJun 04Sale34.033,841130,7044,412,094Jun 07 04:30 PM
Wedell-Wedellsborg JohanDirectorJun 04Sale34.033,841130,7044,412,094Jun 07 04:31 PM
Wedell-Wedellsborg JohanDirectorJun 03Sale33.1930,6661,017,6704,415,935Jun 07 04:31 PM
WG Biotech ApS10% OwnerJun 03Sale33.1930,6661,017,6704,415,935Jun 07 04:30 PM
WG Biotech ApS10% OwnerJun 01Sale35.576,864244,1734,446,601Jun 02 04:31 PM
Wedell-Wedellsborg JohanDirectorJun 01Sale35.576,864244,1734,446,601Jun 02 04:32 PM
Wedell-Wedellsborg JohanDirectorMay 28Sale36.3425,000908,4754,453,465Jun 02 04:32 PM
WG Biotech ApS10% OwnerMay 28Sale36.3425,000908,4754,453,465Jun 02 04:31 PM
Gad ThomasSee remarksMay 28Sale36.954,000147,8131,603,927Jun 01 04:32 PM
Kruse BoEVP, CFO, Secretary & Treas.May 24Sale35.614,000142,440253,077May 26 04:33 PM